Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
In CALI @ 0.012
In HISC @ $0.11
CALI @ $0.012 up 98%
ADH I'll hold till next week these AMEX guys are slow to react to the good news.
Buying more ADH below $0.40
In ADH @ $0.42
Adherex Announces Licensing Deal With GlaxoSmithKline-GSK Makes Equity Investment in Adherex
Friday July 15, 7:30 am ET
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--July 15, 2005--Adherex Technologies Inc. (AMEX:ADH - News; TSX:AHX - News), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that the Company has entered into a licensing and development agreement with GlaxoSmithKline (NYSE: GSK - News) for the in-license by Adherex of GSK's oncology product, eniluracil, and an option for GSK to license Adherex's lead biotechnology compound, ADH-1 (Exherin(TM)). In addition, GSK has invested US$3 million in Adherex's previously announced private placement.
ADVERTISEMENT
Under the agreement, Adherex received an exclusive license to eniluracil for all indications, and GSK retains options to buy back the compound at various points in time during its development. If GSK exercises any of its options on eniluracil, Adherex will receive development and sales milestone payments of up to approximately US$120 million in aggregate, plus up to double-digit royalties, depending upon if and when an option is exercised. If GSK does not exercise its buy-back options, Adherex would be free to develop eniluracil alone or with other partners and would pay GSK development and sales milestone payments and double-digit royalties.
Adherex also agreed to grant to GSK an option to receive a worldwide, exclusive license for Adherex's lead biotechnology compound, ADH-1. If GSK exercises the ADH-1 option and negotiates a license agreement with Adherex, Adherex would receive upfront, development and sales milestone payments of up to approximately US$100 million in aggregate, plus double-digit royalties. ADH-1 is now in Phase Ib/II and Phase II trials after its initial Phase I trial demonstrated encouraging evidence of anti-tumor activity.
"Either of these licensing deals would be of major importance for Adherex alone, but the combination is a transforming event for the Company. We have acquired a product with a significant market opportunity from GSK and have granted an option for our lead biotechnology drug to a major, multi-national pharmaceutical company," said William P. Peters, M.D., Ph.D., Chairman and CEO of Adherex. "The in-licensing of eniluracil provides Adherex with potential 'blockbusters' on both sides of our business: ADH-1 from our cadherin-based biotechnology platform and eniluracil from our specialty pharmaceuticals portfolio."
Peters continued, "Eniluracil adds a late-stage product opportunity with major market potential to Adherex's specialty portfolio, with Phase III development beginning as early as 2007. We believe that eniluracil will make 5-fluorouracil (5-FU), currently a mainstay first-line therapy for many solid cancers, safer, more effective and orally active. If GSK exercises its option for ADH-1, GSK would assume development of the drug which we anticipate would improve the commercial potential of this asset. All told, this deal validates the depth of our knowledge of oncology products and our ability to identify and capitalize on unique opportunities in the oncology arena."
Eniluracil is an investigational drug under development for the treatment of patients with cancer. Eniluracil may enhance the therapeutic value of 5-FU by making the drug orally active with fewer side effects and, based on recently generated preclinical data, has the potential to improve its effectiveness. 5-FU is one of the most commonly used oncology drugs in the world, currently used as first-line therapy for solid tumors, such as colon, rectal, breast, gastric, head and neck, ovarian, and basal cell cancer of the skin, among others. The use of 5-FU in combination with eniluracil may also offer the opportunity to broaden the types of cancer in which 5-FU has been shown to be active.
GSK's clinical development program for the combination of 5-FU and eniluracil met with success in early development. However, two Phase III trials displayed suboptimal efficacy and development was stopped. New scientific data obtained subsequent to those Phase III trials may account for the early suboptimal efficacy and provide a basis for enhancing the effectiveness of the combination. This proprietary data forms the basis of a patent application by Adherex, which claims that the combination of eniluracil and 5-FU has the potential to be more effective than 5-FU alone when used in accordance with Adherex's proprietary and trade secret methods.
ADH-1 targets N-cadherin, a molecule present on certain tumor cells and on the established blood vessels that are the life support of tumors. Importantly, ADH-1 may have utility in a wide variety of cancers where N-cadherin is expressed including breast, lung, ovarian and melanoma, among others.
Conference Call
Adherex will host a conference call today at 11 a.m. ET to discuss recent corporate events including the licensing agreement with GlaxoSmithKline. This call will be webcast live via the Internet at www.adherex.com. The event will also be archived and available for telephone replay through midnight on July 20, 2005 and webcast replay through July 15, 2006.
Live Participant Dial In (Toll Free, Canadian and US callers):
800-946-0713
Live Participant Dial In (International): 719-457-2642
Conference Passcode: 6007418
Replay Number (Toll Free): 888-203-1112
Replay Number (International): 719-457-0820
Replay Passcode: 6007418
About Adherex Technologies
Adherex Technologies Inc. is a biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics. We aim to be a leader in developing innovative treatments that address important unmet medical needs in cancer. We currently have four products in the clinical stage of development, including ADH-1 (Exherin(TM)) and sodium thiosulfate (STS). ADH-1, our lead biotechnology compound, selectively targets N-cadherin, a protein present on certain tumor cells and established blood vessels that feed solid tumors. Importantly, ADH-1 may have utility in a wide variety of cancers where N-cadherin is expressed including breast, lung, ovarian and melanoma, among others. STS, a drug from our specialty pharmaceuticals pipeline, protects against the disabling hearing loss that can often result from treatment with platinum-based chemotherapy drugs. With a diversified portfolio of unique preclinical and clinical-stage cancer compounds and a management team with expertise in identifying, developing and commercializing novel cancer therapeutics, Adherex is emerging as a pioneering oncology company. For more information, please visit our website at www.adherex.com.
This press release contains forward-looking statements that involve significant risks and uncertainties. The actual results, performance or achievements of the Company might differ materially from the results, performance or achievements of the Company expressed or implied by such forward-looking statements. Such forward-looking statements include, without limitation, those regarding the milestone payments and royalties that may become payable to the Company under the agreement with GSK as well as the development plans of the Company and the expected timing and results of such development. We can provide no assurance that such payments will be made or the development will proceed as currently anticipated or that the expected timing or results of such development will be realized. We are subject to various risks, including those inherent in the biopharmaceutical industry, the early stage of our product candidates, the uncertainties of drug development, clinical trials and regulatory review, our reliance on collaborative partners, our need for additional capital to fund our operations, and our history of losses. For a more detailed discussion of related risk factors, please refer to our public filings available at www.sedar.com and www.sec.gov.
Adherex Technologies Inc. (TSX:AHX - News; AMEX:ADH - News)
Contact:
Adherex Technologies Inc.
Melissa Matson
Director, Corporate Communications
(919) 484-8484
matsonm@adherex.com
The news looks good! I'm waiting for some volume before getting in.
BlueBear Network Acquires Breakthrough 3D Face Camera
7/14/05
Fast, Simultaneous 3D and 2D Mugshots Will Improve Forensic Identification
OTTAWA, Jul 14, 2005 (PRIMEZONE via COMTEX) --
BlueBear Network International, Inc. (Pink Sheets:BLBR) announced today it has successfully tested proprietary 3D MugShot camera technology for the law enforcement market worldwide.
The breakthrough technology, acquired from VisionSphere Technologies, is a fast, inexpensive device for simultaneous acquisition of accurate three-dimensional and two-dimensional human faces. It will allow law enforcement and security agencies to capture both types of mug shots in seconds as a single snapshot and provides incredible accuracy in correctly mapping the individual being booked in 3D.
Mr. Michel Duron, Vice President of Marketing for BlueBear points out, "By providing both 3D mug shots and NIST-compliant 2D mug shot, our solution is compatible with booking systems already in place and positions police agencies for dramatic improvements in the accuracy and performance for facial recognition, enhanced ability to match non-frontal suspect's faces from surveillance footage, and many other enhanced identification uses. The device is small, easy to use and transport, and will be available at a fraction of the cost of traditional 3D scanners and devices."
Mr. Duron adds, "At BlueBear Network, we are dedicated to helping law enforcement keep our neighborhoods safe by providing the best biometric identification and information sharing technology available in a way that is easily deployed, totally integrated to existing systems and affordable for all police services from small detachments to large metropolitan police forces."
About BlueBear Network International, Inc.
BlueBear Network International, Inc. is a Nevada-registered company based in Ottawa, Ontario, Canada. BlueBear Network develops and markets the world's first system that uses biometrics and text records to securely and simultaneously search and share biometric and records information among linked police and integrated justice databases. BlueBear Network's system responds to worldwide police and government requirements for the timely and effective information search and sharing in homeland security and law enforcement. The company has established strong strategic relationships with several large manufacturers, software and consulting firms. For more information, visit http://www.bbninternational.com/.
This press release contains forward-looking statements as defined in the Securities Litigation Improvements Act of 1996. The words "believe, expect, estimate and project" and similar expressions define forward-looking statements, which speak only as of the date the statement was made. BBNI undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events or otherwise. Forward-looking statements are currently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated in, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the company's ability to meet its projected growth, the effects of government regulation, competition, and other material risks
SOURCE: BlueBear Network International, Inc.
BlueBear Network International, Inc. Andrew Brewin, President and CEO (613)599-7766, ext. 25 abrewin@bbninternational.com Investors: investors@bbninternational.com 613-599-7766
(C) 2005 PRIMEZONE, All rights reserved.
In EFCR @ $0.10
CAFE is running out of steam .
CAFE is a good short above $9.00
Take care bro! I'll see you in 2 weeks.
In RWNW @ $0.0034
In PGGG @ $1.60 .
In AMPX @ $36.
USA Goes Green Energy with 20 New Biomass Power Plants in 2006
7/13/05
U.K. Coal Power Plant Converts to Co-Firing, Biomass
NEW YORK, Jul 13, 2005 (PRIMEZONE via COMTEX) --
Green Energy Resources (Pink Sheets:GRGR) has confirmed Alstom of Sweden will convert Scottish Southern Energy's (SSE) Power Plant at Fiddlers Ferry Ferry (U.K.), to biomass and co-firing power generation from coal. It will be the largest renewable energy power plant in the U.K. The plant was designed and built by Alstom in the 70s and is scheduled to be operational by the first quarter of 2006. It is one of several U.K. facilities Green Energy Resources has been working with for nearly two years. The conversion of coal-fired plants to co-fired plants, represents over 51% of total energy markets in the world, larger than oil and gas combined. Each power plant conversion represents significant growth potential for Green Energy Resources in the international energy field. Green Energy Resources will address the international coal industry at its 25th anniversary conference in Paris in October.
Nearly two dozen new biomass power plants are scheduled to go on-line in 2006 in the United States. Green Energy Resources has been contacted by numerous power utilities in regard to supplies of biomass throughout the USA, including Florida, Michigan, California, New York, Connecticut, New Jersey, Vermont, and Pennsylvania, to name a few. The Renewable Portfolio Standard (RPS) is very favorable in the northeast, where power generators get both renewable energy credits and tax credits for green energy. Discussions are ongoing. Many of the contacts were developed through the Wall St. Renewable Energy Forum last month in New York City.
Except for historical information contained herein, the statements in this release are forward-looking statements that are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that may cause the companies' actual results in future periods to differ materially from forecasted results. Such risks and uncertainties include, but are not limited to, market conditions, competitive factors, the ability to successfully complete additional financing and other risks.
SOURCE: Green Energy Resources
Green Energy Resources Joseph Murray 1-631-375-7921 joe.murray@greenenergyresources.com www.greenenergyresources.com Worldwide Financial Marketing, Inc. USA Investor Relations Int'l: 1-954-360-9998 Nat'l: 1-866-360-9998 Info@wwfinancial.com
(C) 2005 PRIMEZONE, All rights reserved.
GWIN Inc. Announces Largest Television Sponsorship Deal in Company History; Part of Company Expansion Into Poker Industry
7/12/05
LAS VEGAS, Jul 12, 2005 (BUSINESS WIRE) --
GWIN Inc. (OTCBB: GWNI) Chairman & CEO Wayne Allyn Root announced today the largest television sponsorship deal in company history. BOSPoker.net has agreed to a be a major sponsor of GWIN's TV show, "Wayne Allyn Root's WinningEDGE," airing on Saturday mornings on Superstation WGN starting September 10. BOSPoker.net is an informational poker Web site for fun, entertainment and prizes only, owned by BETonSPORTS.com, a publicly-traded gaming firm based in the United Kingdom and traded on the London-based AIM Stock Exchange (BSS.L). BOS is one of the largest sports gaming companies in the world. BOSPoker.net is the newest venture by BOS into the lucrative world of poker. The announcement comes during the World Series of Poker, which has become the richest sporting event in the world with more than 29,000 participants and more than $100 million in the net prize pool. The agreement includes sponsorship of both "Wayne Allyn Root's WinningEDGE" national TV and radio properties.
GWIN Chairman & CEO Wayne Allyn Root said of the deal, "We have been reporting for months now that GWIN is no longer a niche sports handicapping company. While we are continuing to build our core sports handicapping services and products business, we are adding new revenue streams from poker, horse racing, TV sponsorship and advertising partners, and the production of high-quality television programming. Poker programming is now aired on a dozen American TV networks. This deal with BOSPoker.net is the largest sponsorship deal in GWIN history. It comes on the heels of our announcement that GWIN plans to become heavily involved in poker -- the most high profile and fastest growing form of gaming in the world today. This sponsorship deal lends more credibility to the power and branding of our WinningEDGE products and personalities. When it comes to gambling advice and information, GWIN is now a global leader."
Said BetOnSports CEO David Carruthers, "BOS is a big fan of Wayne Allyn Root and The WinningEDGE brand names. We believe he is the brand name in American sports handicapping and represents the positive image of global gaming. We are excited to be associated with Wayne and GWIN's high-quality television and radio programs, 'Wayne Allyn Root's WinningEDGE.' This sponsorship deal is another step in promoting the BOS brand and our new BOSPoker.net product to American consumers. Poker is exploding in popularity and we believe attaching our new online poker information and entertainment site to a nationally recognized gaming personality like Wayne Allyn Root and The WinningEDGE is a winning formula."
About BOS
BETonSPORTS plc, one of the world's leading online and telephone sports book, casino and poker operators, is committed to providing its clients with the most value for their wagering dollar and quality customer service capabilities. Headquartered in San Jose, Costa Rica, the company is licensed in the Caribbean, Central America and Europe, and has obtained a bookmakers permit in the United Kingdom, where gambling has been a legal and respected tradition for more than 40 years. At the peak of high season in the financial year ended Jan. 31, 2004, it employed over 1,600 employees in Antigua, Costa Rica, the Dominican Republic and the United Kingdom. The company trades under the symbol BSS.L on the London Stock Exchange's Alterative Investment Market. BETonSPORTS.com has been ranked the No. 1 sports book by a number of leading industry organizations, including the Offshore Gaming Association (OSGA), the International Sports Book Council (ISBC) and Insiders Football Guide. Visit www.BETonSPORTS.com for more information.
About GWIN
GWIN Inc. is America's only publicly traded sports handicapping company. GWIN specializes in developing and marketing sports handicapping advice and information via television (Wayne Allyn Root's WinningEDGE(TM)), radio, and the Internet (www.WinningEDGE.com) and producing sports and gaming programming.
Safe Harbor Statement -- The above news release contains forward-looking statements. These statements are based on assumptions that the management of GWIN Inc. believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of GWIN Inc. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and are subject to a wide range of business risks, external factors and uncertainties. Actual results may differ materially from those indicated by such forward-looking statements. GWIN Inc. assumes no obligation to update the information contained in this press release, whether as a result of new information, future events or otherwise.
SOURCE: GWIN Inc.
GWIN Inc., Las Vegas Douglas R. Miller, 702-967-6000 www.winningedge.com
Copyright Business Wire 2005
All out GRYF @ $0.0053
In BSIO @ $0.043
AOBO same story as LENF. LENF went up big yesterday because of the AMEX listing.
US Financial Network: Genentech announces second quarter profit and ID Biomedicals flu vaccine granted fast track by FDA
7/12/05
Jul 12, 2005 (M2 PRESSWIRE via COMTEX) --
City of Industry, CA - Biotechnology industry news provided by Financial News USA (OTC: FNWU). Shares of Genentech Inc. (NYSE: DNA) rose Tuesday, a day after the biotechnology company reported its second-quarter profit surged 73 percent, fueled by continued strong drug sales. The company's stock rose $1.13, or about 1.4 percent, to $84.63 in early trading on the New York Stock Exchange. ID Biomedical Corporation (NASDAQ: IDBE) announced today it has been advised by the United States Food and Drug Administration's Center for Biologics Evaluation and Research (CBER) that the Company's Influenza Virus Vaccine (Fluviral(TM)) has been granted a Fast Track designation.
U.S. BioDefense (OTC BB: UBDE) is pleased to announce recently that it has signed a six (6) month option to license world patent application WO 03/054202 A1 and U.S. patient application 5,958,767 entitled "Generation of Human Neural Crest Stem Cell Line and Its Utilization in Human Transplantation" and related applications with the University of British Columbia developed by Dr. Seung Kim in the Department of Neurology at UBC. U.S. BioDefense joins StemCells, Inc. (Nasdaq: STEM) as the only two major public companies to pioneer Neural Crest Stem Cell technology in the United States.
About Financial News USA
Financial News USA is a Next Generation Financial Communications firm focused on the distribution of market moving news. Financial News USA has developed leading edge e-publishing tools including programming proprietary RSS feeds and enabling open source press release publishing across its network. Financial News USA has been aggressively expanding its news distribution network by targeting direct feeds to financial news and data providers such as FinancialContent, Yahoo (NASDAQ: YHOO), among others. Financial News USA offers a free news feed available online (www.financialnewsusa.com) to websites and financial services looking for content and for individual investors looking to stay informed on the financial markets. Financial News USA and its affiliates charge each client cash for news distribution and may take an equity position in the companies mentioned herein, please visit the disclaimer at www.financialnewsusa.com.
CONTACT: Financial News USA Tel: +1 626 961 8041 e-mail: info@financialnewsusa.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
(C)1994-2005 M2 COMMUNICATIONS LTD
Nice! I know you own a lot of UCHB shares.
GRYF @ $0.0065 up 58% Holding free shares now!
BCIT maybe another 10 bagger from here just like few months ago.
If not at least a tripler we will find out soon.
Art Nice board!
Hudson's Grill Announces the Opening of a New Hudson's Grill Restaurant in Appleton, Wisconsin
7/11/05
DALLAS, Jul 11, 2005 (PRIMEZONE via COMTEX) --
Hudson's Grill International, Inc. (OTCBB: HGIIA), based in Dallas, Texas, announced today that on July 5, 2005, Vissions, Inc., a corporation owned by Jim and Lisa Stabile, opened a new Hudson's Grill restaurant. The new restaurant is located at 1950 North Casaloma Drive, Appleton, Wisconsin. Mr. Stabile is already very familiar with the operations of a Hudson's Grill restaurant. He had managed the Hudson's Grill located in Marquette, Michigan, from April 1999, when it opened, until November 2004. Jim Stabile is also a consultant with Hudson's Grill International, handling oversight and sales of franchises in the Upper Midwest.
Franchisees of the company have now opened three new Hudson's Grill restaurants in the Upper Midwest this year. Besides the new Appleton, WI, restaurant just opened by Mr. Stabile, franchisees opened restaurants this year in DePere, WI, and Dubuque, IA. Hudson's Grill International now has seven franchised Hudson's Grill restaurants operating in the Upper Midwest, where it appears to be meeting with more and more success.
Hudson's Grill International is a public company. The company's class A common shares are currently being quoted and traded over the counter on the bulletin board under the NASD symbol HGIIA.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995.
"This press release may contain forward looking statements relating to future events or future financial performance that involve risks and uncertainties. Such statements can be identified by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of such terms or comparable terms. These statement are only predictions and actual results could differ materially from those anticipated in these statements based upon a number of factors including those identified in the Company's filings with the SEC."
SOURCE: Hudson's Grill International, Inc.
MicroTRAK, Inc. Goes Coast to Coast Receiving Two Hefty Orders from Large National Distributors
7/11/05
DALLAS, Jul 11, 2005 (BUSINESS WIRE) --
MicroTRAK, Inc. (Pink Sheets:MIOK) has just received a large order for one of MIOK's biggest products, the portable, pocket-size, and self-contained GPS asset location device. The MIOK GPS portable can be attached to virtually anything and located anywhere in North America within 40 feet of its actual location. The portable units will be sent to Thunderball Marketing, Inc. (TMI) and an even larger order will be sent to Talley Communications Corp. (TCC).
Thunderball Marketing is one of the country's largest distributors of mobile audio, professional and consumer electronics for the past two decades. TMI has years of experience in breaking new technology and is tremendously excited about the opportunity to bring MIOK's portable asset location solution to the marketplace/large dealer base. Joe Levy, VP of TMI, duly noted: "The new MicroTRAK portable device will be a great addition to our lineup of top notch mobile audio products and my dealers are excited about the product itself and the fact that we will be distributing this line. We look forward to a long relationship and successful selling of their highly technical items."
Talley Communications Corp. is a leading distributor in wireless communications infrastructure and communication products for more than 20 years. TCC currently has five large warehouses located in Arizona, Northern and Southern California, Washington State and Kansas. TCC will be selling and distributing the new GPS portable asset location device through their sales and customer service personnel, who have had more than 20 years of industry experience.
For more information about MIOK, please visit the company's website at www.microtrakgps.com.
This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities and Exchange Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainties. Although MicroTRAK Inc. believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any assumption could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion should not be regarded as a representation by MicroTRAK Inc. or any other person that the objective and plans of MicroTRAK Inc. will be achieved.
SOURCE: MicroTRAK Inc.
MicroTRAK Inc. Jerry Grisaffi, 214-999-1249 info@IrisDirectllc.com irisdirectllc.com
Copyright Business Wire 2005
© 2005 Stockgroup Media Inc. / Disclaimer
GRYF @ $0.0039 hod! Bought some @ $0.0025 .
GRYF @ $0.0035 UP 105%
In BCIT @ $0.003
In CIRT @ $0.038 Out CYBL @ $0.09 for a small loss.
In CYBL @ $0.1050
Novartis Submits Applications in U.S. and Europe for Femara as Adjuvant Treatment for Postmenopausal Women With Early Breast Cancer
7/11/05
Applications Based on Data From Large Head-to-Head Trial Showing Femara is More Effective Than Tamoxifen in Helping These Women Stay Cancer Free
BASEL, Switzerland, Jul 10, 2005 (PRIMEZONE via COMTEX) --
Pre-Planned Subset Analyses Show Femara Reduces Risk of Cancer Returning by Up to 30% in Node-Positive and Chemotherapy-Treated Patients
Novartis (NYSE:NVS) has submitted marketing authorization applications in the United States and Europe for the use of Femara(r) (letrozole) in the adjuvant (post-surgery) treatment of postmenopausal women with hormone receptor-positive early breast cancer.
Once approved for this indication, Femara will become the only breast cancer treatment available to significantly reduce the risk of recurrence in the adjuvant setting as well as in extended adjuvant treatment following tamoxifen.
"Femara represents an important advance to help increase a woman's chance of staying cancer free after initial treatment for early breast cancer," said Diane Young, MD, vice president and global head, Clinical Development, Novartis Oncology. "The data filed today add to the already substantial body of evidence supporting the use of Femara in breast cancer."
The submissions are based on data from the Breast International Group (BIG) 1-98 study, a Phase III, randomized, double-blind study that compared the safety and efficacy of adjuvant Femara vs. tamoxifen in more than 8,000 postmenopausal women with hormone receptor-positive early breast cancer. The overall results of BIG 1-98 demonstrated that at a median follow-up of 26 months, Femara prolonged disease-free survival by reducing risk of recurrence by an additional 19% (p=0.003)(a) over the reduction offered by tamoxifen. Women who were treated with Femara experienced a 27% reduction in the risk that their cancer would spread to other parts of the body (distant metastases) compared with tamoxifen (p=0.001), a clinically relevant finding since women who develop distant metastases may be at greater risk of dying from their disease. Femara also provided a 14% reduction in the risk of death, although this did not reach statistical significance (p=0.155).
In two separate pre-planned subset analyses, Femara also reduced the risk of cancer returning by 29% among patients whose initial cancer had already spread to the lymph nodes at the time of diagnosis (node-positive breast cancer) and by 30% in those who had received chemotherapy, two groups that are at increased risk of recurrence. Additionally, in node-positive patients and in patients who received adjuvant chemotherapy, the risk of distant metastases was reduced by more than 30% with Femara compared to tamoxifen.
About BIG 1-98
BIG 1-98 is the only clinical trial designed to incorporate both a head-to-head comparison of Femara with tamoxifen during the first five years following breast cancer surgery and a sequencing of both agents to determine the most effective approach to minimizing the risk of recurrence. Patients were randomized to the following arms: tamoxifen for five years, Femara for five years, tamoxifen for two years followed by Femara for three years, and Femara for two years followed by tamoxifen for three years. Results from the ongoing arms of the study, which are expected to determine whether monotherapy or sequential therapy is more effective, and if sequential therapy, which sequence is more effective, are expected in 2008.
BIG 1-98 was conducted by the International Breast Cancer Study Group (IBCSG), with participation of the Danish Breast Cancer Group, the French FNCLCC group, the Yorkshire Group and many independent centers. The study was supported by Novartis.
The data upon which the filings are based were initially presented at the Primary Therapy of Early Breast Cancer 9th International Conference in St. Gallen, Switzerland, in January 2005. Updated data from this analysis, presented in May at the annual meeting of the American Society for Clinical Oncology (ASCO) in Orlando, Florida, clarified the safety of Femara as compared with that of tamoxifen.
The adverse events in the BIG 1-98 study were consistent with published data on both Femara and tamoxifen. In the BIG 1-98 study, the two treatments were generally well tolerated and the safety profile in the two treatment arms was similar. Only arthralgia/arthritis, bone fractures and osteoporosis were significantly more common in the Femara arm as compared to tamoxifen. Hot flashes/flushes, night sweats, vaginal bleeding and thromboembolic events in turn were significantly more frequent in the tamoxifen group.
Overall, more deaths were reported on tamoxifen (n=192) than on Femara (n=166). More patients on tamoxifen (n=135) died from breast cancer than Femara (n=100). In patients whose breast cancer did not recur, more deaths due to cardiac causes were reported in Femara-treated patients than tamoxifen-treated patients.
The frequency of bone fractures and osteoporosis on both treatments was low but the numbers were higher in the Femara arm (6.4%) compared to tamoxifen (4.8%). Endometrial hyperplasia or cancer was reported more often for tamoxifen (2.1%) than for Femara (0.4%).
In the trial, the number of all cardiovascular events was overall lower in the Femara arm than in the tamoxifen arm (9.7% vs. 10.5%). Irrespective of causality, the following adverse events occurred in the Femara and tamoxifen groups respectively: thromboembolic events (1.2% vs. 2.8%), angina pectoris (0.7% vs. 0.6%), myocardial infarction (0.6% vs. 0.4%) and cardiac failure (0.9% vs. 0.4%). Tamoxifen slightly decreased the cholesterol values, whereas Femara treatment resulted in no relevant overall changes over time in serum total cholesterol.
About Femara
Femara is a leading once-a-day oral aromatase inhibitor currently available in more than 90 countries worldwide. Femara is approved for extended adjuvant treatment of early breast cancer in postmenopausal women who have completed standard adjuvant tamoxifen therapy in 57 countries worldwide, including Europe as well as the United States. In addition, it is indicated for first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer and for the treatment of advanced breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, and as neo-adjuvant (pre-operative) therapy. Not all indications are available in every country.
Contraindications, warnings and adverse events
In previous clinical trials, the most common adverse events experienced with Femara have been hot flashes/flushes, arthralgia/arthritis and myalgia. Other commonly reported adverse reactions are: nausea, fatigue, anorexia, appetite increase, peripheral edema, headache, dizziness, vomiting, dyspepsia, constipation, diarrhea, alopecia, increased sweating, rash, bone pain, weight increase, osteoporosis and bone fracture.
Femara is contraindicated in women who are pregnant or breast-feeding as well as in premenopausal women. Femara is contraindicated in patients with known hypersensitivity to Femara or any of its excipients.
The foregoing release contains forward-looking statements that can be identified by terminology such as "once approved," "will become," "important advance," "to help increase," "are expected" or similar expressions, or by express or implied discussions regarding potential new indications, marketing approvals, or future sales of Femara. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results with Femara to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Femara will be approved for any additional indications in any market, nor that it will reach any particular sales levels. In particular, management's expectations regarding commercialization of Femara could be affected by, among other things, additional analysis of Femara clinical data; new clinical data; unexpected clinical trial results; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; increased government, industry, and general public pricing pressures; and other risks and factors referred to in the Company's current Form 20-F on file with the U.S. Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
For more information
Additional information regarding Femara or Novartis Oncology can be found on the websites www.femara.com or www.novartisoncology.com. Additional media information can be found at www.novartisoncologyvpo.com.
About Novartis
Novartis AG (NYSE:NVS) is a world leader in pharmaceuticals and consumer health. In 2004, the Group's businesses achieved sales of USD 28.2 billion and pro forma net income of USD 5.6 billion. The Group invested approximately USD 4.2 billion in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 81,400 people and operate in over 140 countries around the world. For further information please consult http://www.novartis.com.
(a) 21% (p=0.002) in U.S. filing due to slightly different definition of disease-free survival by U.S. health authorities.
http://hugin.info/134323/R/1001822/153536.pdf
SOURCE: Novartis
Novartis Oncology Kim Fox (862) 778-7692 (direct) kim.fox@novartis.com Novartis Global Media Relations John Gilardi +41 61 324 3018 (direct) +41 79 596 1408 (mobile) john.gilardi@novartis.com
(C) 2005 PRIMEZONE, All rights reserved.
© 2005 Stockgroup Media Inc. / Disclaimer
Digital Gas Partners with ICCU of the Netherlands to Usher in Grid Enhancing Power Storage Breakthrough
7/8/05
NEW YORK, Jul 08, 2005 (BUSINESS WIRE) --
Digital Gas, Inc. (OTC Pink Sheets:DIGG) announced today that it will partner with ICCU of the Netherlands to manufacture and market the world's most advanced ultracapacitor. The parties will initially operate under the corporate name "Digital Ultracap". The new, low-cost energy storage device is ready for market this year. It has the potential to revolutionize the use of "Green Power" and "Distributed Generation," as well as to improve the robustness and efficiency of the traditional electric power grid. These devices promise to become a standard appliance in commercial and industrial buildings and in every home in America. Other participants in ICCU include a major European bank, a major European utility, an international construction company and an international metals company.
ICCU's ultracapacitor has achieved an unheard of price breakthrough per kilowatt hour of storage capacity and can operate over a minimum thirty-year lifetime with zero maintenance. The Ultracap will provide an affordable buffer between utility power generation capacity and power consumption on a massive scale. It is estimated that this type of device can save up to fifteen billion dollars ($15 Billion) annually on America's estimated two hundred billion dollar ($200 Billion) annual electric bill.
The new ultracapacitor will allow utilities to optimally match their customers fluctuating demand to the generation plant. Since power consumption varies substantially over the course of a 24-hour period, as well as seasonally, it has been necessary to oversize the total power generation capacity in order to meet maximum power consumption periods, especially when, for example, air conditioning loads rise dramatically during hot summer days. These maximum power consumption periods are what lead utilities to initiate so-called rolling brown-outs and, under extreme conditions, even blackouts, in order to prevent a total collapse of the power delivery system for a particular geographic region.
The use of Digital Ultracap's product will improve the robustness of the grid and permit significant amounts of less reliable distributed co-generation to be added to the grid better than any product expected to penetrate the market in the foreseeable future. In addition, this affordable, reliable, robust and long-lived energy storage unit will permit the operation of remote power facilities that depend on local renewable generation without access to the grid. This is particularly important in the case of where the cost of transportation of the back-up fossil fuels is significant and for developing countries deploying solar and wind generators. As such, the new ultracap will greatly assist the economy and proliferation of renewable power generation technologies such as wind power, solar power, and tidal power generating devices, as well as hybrid power generation technologies such as micro-CHP (combined heat/power) and fuel-cells. The new ultracapacitor will efficiently store the energy produced until it is needed for use. For example, the wind does not necessarily blow and the sun does not necessarily shine at those moments when the resulting power generated is required for consumption.
The ultracap will allow utilities to minimize the power generation capacity on hand since they can now economically store electricity that can be instantly tapped when either a spike occurs in electric consumption by their industrial, commercial and residential customers or there is unforeseen equipment downtime. This ultracapacitor buffer also allows utilities to operate their generators at maximum efficiency as opposed to ramping power generation up and down which results in less economic consumption of fossil fuels burned by their generators. This ramping up and down in turn contributes to unnecessary production of greenhouse gas (carbon dioxide). Theoretically, utilities could even decommission power generators if sufficient widely distributed energy storage capacity were available. This storage capacity would allow them to operate their generators night and day at a relatively constant output at their highest efficiency fuel and emissions efficiency, thereby lowering their base power generation capacity need. Home owners that buy the product can realize the advantage of buying electricity at off-peak prices and using it during peak usage hours.
The Department of Energy is promoting the implementation of distributed generation technology along with renewable power generation. Distributed generation plants can more readily significantly reduce the amount of greenhouse gases compared to typical central power plants. Central power plants more often than not have no local users for the waste heat. Distributed generation can virtually cut in half the amount of greenhouse gases produced vis-a-vis central power plants. This emission reduction of carbon dioxide is possible because conventional power generation devices normally convert half of the fuel consumed to waste heat that is vented to the atmosphere. If, on the other hand, the power generator is located at the site where the power is consumed, the heat that would normally be vented to the atmosphere can be instead utilized for space heating or hot water heating, among other useful applications. Digital Gas' farming centers, for example, that are planned for the previously announced East St. Louis waste-to-energy plant, can utilize waste heat for greenhouses and aquatic farming.
Where applicable, the ultracap will present an immediate emissions reduction and trading opportunity for utilities. Due to their higher efficient power generation, utilities can gain valuable carbon-credits to be traded on international markets. Currently, a metric ton (2200 lbs.) is traded around twenty dollars per ton per year coming up from eight dollars per ton in 2004. Consulting companies project the price to rise to eighty dollars per metric ton per year in 2008.
The ultracapacitor is so unusual in its price and performance characteristics that it represents a totally new class of energy storage technology. Digital Gas, which is partnering with ICCU to commercialize the ultracapacitor in North and South America and other markets to be announced, intends to work closely with major utilities, as well as local, state and national governments to rapidly and fully exploit the environmental and economic benefits of the storage technology. Digital Ultracap's product, which can store electricity with 95% efficiency, can currently offer utilities energy storage systems at approximately $400 per kWh, including power electronics. Existing flow-battery systems store energy with only 80-85% efficiency. Over time, this difference in efficiency translates into a significant operating cost difference.
One major opportunity that the ultracapacitor represents to utilities is the ability to store energy in such massive quantities that the otherwise unavoidable upgrade of the grid, estimated to cost approximately one hundred billion dollars ($100 Billion), can be reduced by a substantial percentage. The US grid itself represents a total investment of approximately one trillion dollars ($1 Trillion) and must be not only constantly maintained, but also continually expanded to meet power consumption growth of approximately 2.5 percent per year. If the ultracapacitor can reduce this upgrade cost of even a few percent, Billions can be saved and valuable real estate and critical wildlife areas not be subjected to use as power corridors or sites for additional generation plants.
Digital Ultracap intends to demonstrate its technology for federal and state energy officials, as well as for executives of utilities facing rapidly escalating cost of peaking fuels and increasing costs of environmental compliance. The new ultracap represents an opportunity to substitute power generation capacity with energy storage capacity, a considerably cheaper alternative in terms of cost per kWh.
"I am looking forward to working with Digital Gas and its in-house energy technologists to market these products throughout North and South America," said Theo van Bakkum, President and CEO of ICCU. Mr. van Bakkum indicated that this ultracapacitor is a dramatic improvement over competing energy storage devices and anticipates that his company's intellectual property provides a cushion of several years' market leadership.
ICCU's ultracap is itself "Green". It contains no heavy metals, no chemicals and no fumes, has fast upload and discharge, has improved power quality on frequency and voltage, has improved reliability, security and comfort, stackable variable capacities and an extremely long life cycle.
"Our product can be marketed now as an uninterrupted power supply or bridge for relatively large applications, for renewable and hybrid power generation, for the automotive market in cars and trucks to provide consistent starting power under all weather conditions and other applications," said Mr. van Bakkum. "There are no effective competitors expected within the next few years because of the long R&D lead-time and our patents and know-how. Much like Dell computer, if competition shows up we will have a tremendous mass production and sales volume advantage that will allow us to defend our market share with extremely competitive pricing," added Mr. van Bakkum.
To enhance the financial condition of the company in the first year, Digital Gas will contribute producing and highly prospective coal bed methane properties for the purpose of providing the new business with internally generated cash flow. Its target will be to contribute properties that are producing $20 million after tax annually by the first quarter of 2006. This will make the immediate investment in Digital Ultracap even more attractive to the major investors that Digital Gas' financial agents and investment bankers are negotiating with. Digital Gas is negotiating with several large investment groups and public companies with excess cash interested in pursuing a reverse merger for Digital Ultracap with a publicly traded company. This will result in a significant stock dividend for Digital Gas shareholders if the company decides to spinout its ownership to them.
Digital Gas is now evaluating several US manufacturing entities with excess capacity. It is planning to commence automated production of the ultracap at commercial volumes in late 2005 or early 2006. A leading candidate for initial production is a 500,000-plus square-foot electronics manufacturing facility. Sales are projected to hit one billion seven hundred million dollars ($1.7 Billion) annually by 2010. The facility would also be used to manufacture the low temperature and high temperature solid oxide fuel cell systems that it anticipates will both complement the ultracapacitor product and be used for a variety of stand alone purposes, including gas processing or the residential, small business, entertainment, hospitality and commercial real estate markets, as well as for enhanced oil & gas recovery in situ.
Major utilities, potential large corporate customers and local, state and federal governments may express interest or inquire further at our email address below.
SOURCE: Digital Gas, Inc.
Digital Gas, Inc. Brian Smith, 732-927-4073 energei@optonline.net
Copyright Business Wire 2005
© 2005 Stockgroup Media Inc. / Disclaimer
Greyfield: Investor Relations Hotline Activated, New Transfer Agent Appointed
Thursday July 7, 7:30 am ET
Revenue Numbers Releasing Next Week
KAMLOOPS, British Columbia--(BUSINESS WIRE)--July 7, 2005--Greyfield Capital Inc.'s (Pink Sheets: GRYF - News) investor relations hotline will be active as of Monday, July 11, 2005. Investors can receive information about the company by calling 415-738-6950.
Greyfield has also appointed National Stock Transfer as the new transfer agent. At this time, the new transfer agent is compiling a share structure report. This report should be ready shortly. Shareholders are encouraged to communicate with the transfer agent directly in order to receive the most current report on the share structure of the company.
In addition, Greyfield shall be releasing its revenue numbers for the month of June next week.
During the last 48 hours, the company has been inundated with a large number of investor questions via e-mail. The company is doing its best to respond to each and every e-mail. Your patience in this matter is appreciated.
New management of Greyfield is committed to having an open relationship with all of its shareholders.
Greyfield Capital is quoted on NQB Pink Sheets as "GRYF."
About Greyfield Capital
Canadian Autorama is a highly profitable, fast-growing premium automobile dealership in Canada. Canadian Autorama has been in operation for the last three years and has experienced explosive growth and is quickly becoming the largest automobile dealership in central Canada.
CAUTIONARY STATEMENT: This news release may include forward-looking statements within the meaning of Section 21E of the United States Securities Exchange Act as amended, and/or the U.S. Private Securities Litigation Reform Act of 1995. All statements involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements that involve various risks and uncertainties. All forward-looking statements in this release are expressly qualified by this notice.
Contact:
Greyfield Capital Inc.
O'Bell, 415-738-6950
info@theautorama.com
Source: Greyfield Capital Inc.
Versar Awarded 10 Year Contract to Support the Air National Guard
Friday July 8, 1:33 pm ET
SPRINGFIELD, Va., July 8 /PRNewswire-FirstCall/ -- VERSAR, Inc. (Amex: VSR - News) announced today that it has been awarded a 10 year contract with the National Guard Bureau to provide environmental engineering, remediation and professional services for the Air National Guard. This is one of four small business awards. The contract is an indefinite delivery/indefinite quantity contract with an estimated capacity of $598 million over a ten year period.
Dr. Ted Prociv, President and CEO of Versar stated, "This award represents a tremendous opportunity to provide services to the Air National Guard nationwide. Supporting our armed services in executing their mission to protect the homeland is a great honor and responsibility that Versar will meet with all its resources."
Versar, Inc., headquartered in Springfield, VA, is a publicly held professional services firm supporting government and industry in national defense/homeland defense programs, environmental health and safety and infrastructure revitalization. Versar operates a number of web sites, including the corporate Web sites, http://www.versar.com , http://www.homelanddefense.com , and http://www.geomet.com ; and a B2B portal for homeland defense products and services, http://www.nbcprotect.com and http://www.dtaps.com .
This press release contains forward-looking information. The forward- looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be significantly impacted by certain risks and uncertainties described herein and in Versar's Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended June 30, 2004.
Contact: James Dobbs (703) 642-6712
Senior Vice President
Email: jdobbs@versar.com
Investor Relations Contact: Andrew J. Kaplan (732) 747-0702
Barry Kaplan Associates
623 River Road
Fair Haven, NJ 07704
Email: smallkap@aol.com
Source: Versar, Inc.
IMDS some late reaction to yesterday's good news. If it breaks $0.30 then it should break out.
IFDG @0.063 up 215% hod . Too late to get in now.
KTWO if it breaks $0.11 with some volume then It will be a good time to get in.
UCHB bot some more @ $0.27 should bounce any time now.